Japanese Drug Makers Switch To Reliance On Generics Sales
This article was originally published in PharmAsia News
Executive SummarySeveral Japanese drug makers see greater opportunities in the generics market this year as major drugs begin losing patent protections. Some of the expirations are faced by Japanese makers themselves, including Daiichi Sankyo's bacteria fighter Cravit (levofloxacin) and Otsuka Pharmaceutical's ulcer treatment Mucosta (rebamipide). They, and AstraZeneca KK's cancer drug Casodex (bicalutamide) also losing its patent protection, boasted annual sales in the $500 million range. Sawai Pharmaceutical is set to take advantage of the expirations and a government emphasis on prescribing generics, with 34 generics set to be launched by the end of May. Towa Pharmaceutical plans 14 and Nichi-Iko Pharmaceutical 26. (Click here for more - a subscription may be required
You may also be interested in...
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.